Basis for Early and Preferential Selection of the E138K Mutation in HIV-1 Reverse Transcriptase
Open Access
- 1 October 2013
- journal article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 57 (10), 4681-4688
- https://doi.org/10.1128/aac.01029-13
Abstract
E138K, a G→A mutation in HIV-1 reverse transcriptase (RT), is preferentially selected by etravirine (ETR) and rilpivirine over other substitutions at position E138 that offer greater drug resistance. We hypothesized that there was a mutational bias for the E138K substitution and designed an allele-specific PCR to monitor the emergence of E138A/G/K/Q/R/V during ETR selection experiments. We also performed competition experiments using mutated viruses and quantified the prevalence of E138 minority species in drug-naive patients. E138K, as well as E138G, consistently emerged first during ETR selection experiments, followed by E138A and E138Q; E138R was never selected. Surprisingly, E138K was identified as a tiny minority in 23% of drug-naive subtype B patients, a result confirmed by ultradeep sequencing (UDS). This result could reflect a low fitness cost of E138K; however, E138K was one of the least fit substitutions at codon E138, even after taking into account the deoxynucleoside triphosphate pools of the cells used in competition experiments. Further UDS analysis revealed other minority species in a pattern consistent with the mutational bias of HIV RT. There was no evidence of APOBEC3-hypermutation in these selection experiments or in patients. Our results confirm the mutational bias of HIV-1 in patients and highlight the importance of G→A mutations in HIV-1 drug resistance evolution.Keywords
This publication has 48 references indexed in Scilit:
- Subunit-Selective Mutational Analysis and Tissue Culture Evaluations of the Interactions of the E138K and M184I Mutations in HIV-1 Reverse TranscriptaseJournal of Virology, 2012
- In Vitro Resistance Profile of the Candidate HIV-1 Microbicide Drug DapivirineAntimicrobial Agents and Chemotherapy, 2012
- Accurate sampling and deep sequencing of the HIV-1 protease gene using a Primer IDProceedings of the National Academy of Sciences, 2011
- MEGA5: Molecular Evolutionary Genetics Analysis Using Maximum Likelihood, Evolutionary Distance, and Maximum Parsimony MethodsMolecular Biology and Evolution, 2011
- Characterization of the E138K Resistance Mutation in HIV-1 Reverse Transcriptase Conferring Susceptibility to Etravirine in B and Non-B HIV-1 SubtypesAntimicrobial Agents and Chemotherapy, 2011
- A new bioinformatics analysis tools framework at EMBL-EBINucleic Acids Research, 2010
- TMC278, a Next-Generation Nonnucleoside Reverse Transcriptase Inhibitor (NNRTI), Active against Wild-Type and NNRTI-Resistant HIV-1Antimicrobial Agents and Chemotherapy, 2010
- Apricitabine Does Not Select Additional Drug Resistance Mutations in Tissue Culture in Human Immunodeficiency Virus Type 1 Variants Containing K65R, M184V, or M184V plus Thymidine Analogue MutationsAntimicrobial Agents and Chemotherapy, 2009
- Conserved Footprints of APOBEC3G on Hypermutated Human Immunodeficiency Virus Type 1 and Human Endogenous Retrovirus HERV-K(HML2) SequencesJournal of Virology, 2008
- Cytidine deamination induced HIV-1 drug resistanceProceedings of the National Academy of Sciences, 2008